At a recent lunch symposium held in conjunction with the 1st Malaysian Advances in Women’s Health Congress 2016, Professor Dr Jamiyah Hassan imparted clinical updates and strategies for the optimization of hormone replacement therapy in menopausal women. Highlights from her presentation are summarized below.
Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.
At the recent Malaysian Osteoporosis Society 2016 Clinical Practice Guideline (CPG) Meeting held on the 8th of October 2016 at Ibis Styles Ipoh, Dr Hew Fen Lee and Professor Dr Chan Siew Pheng presented clinical guidance on the management of osteoporosis, and discussed whether the benefits of treatment outweigh the risks.
At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).
Preventing hypertension, diabetes, and obesity, which are the major risk factors for heart failure (HF), by ages 45 and 55 years may lower risks of incident HF and prolong HF-free survival, suggests data from the Cardiovascular Disease Lifetime Risk Pooling Project.
The prevalence of hypertension is on the rise in Malaysia and many patients require more than one medication to control their BP. However, treatment adherence is a common issue in patient management, particularly when it comes to patients with multiple morbidities requiring numerous medications.1 In this interview, MIMS Doctor spoke to a distinguished endocrinologist about systolic hypertension, diabetes and patient compliance.
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
The Malaysian drug armamentarium for diabetes welcomed its most recent addition with the launch of the first and only metformin XR + sodium glucose cotransporter (SGLT) 2 inhibitor (Xigduo XR®, AstraZeneca) combination therapy in Malaysia. The glittering event witnessed four esteemed speakers share their views on the need to intensify the battle against the disease.
Type 2 diabetes (T2D) appears to be much more aggressive in youths, with beta cell function deteriorating much more quickly than in adults with T2D even with combination treatment, suggested the TODAY* study, key findings of which were presented at the recent ASEAN Federation of Endocrine Societies (AFES) meeting.
The inclusion of statins in managing chronic kidney disease (CKD) may help reduce patient mortality from stroke and possibly other cardiovascular events, according to an expert at the 7th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress.